| Nov 11 |
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment
|
| Nov 11 |
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
|
| Sep 5 |
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 5 |
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
|
| Aug 13 |
Sidoti Events, LLC's Virtual August Micro-Cap Conference
|
| Aug 13 |
Citius merges oncology subsidiary with TenX Keane
|
| Aug 13 |
Citius Pharmaceuticals GAAP EPS of -$0.06 misses by $0.01
|
| Aug 12 |
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
|
| Aug 12 |
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
|
| Aug 12 |
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
|
